NCT01511497

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study Of PF-04427429 In Healthy Women Volunteers

A Randomized, Placebo Controlled, Double-Blind, Third Party Open, Ascending Dose Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429 Administered Intravenously To Healthy Female Adult Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 31 (actual)
• Sponsor: Pfizer · Industry
• Sex: Female
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-04427429 in healthy women.

Conditions

• Pain
• Migraine Disorders

Interventions

Type	Name	Description
BIOLOGICAL	PF-04427429	Intravenous, single dose given over 1 hour with experimental dose. Subjects can receive one of four potential doses - 300, 1000, 1500 or 2000 mg.
OTHER	Normal saline	Intravenous, normal saline

Timeline

• Start date: 2011-10-01
• Primary completion: 2013-01-01
• Completion: 2013-01-01
• First posted: 2012-01-18
• Last updated: 2013-02-21

Locations

3 sites across 1 country: United States